Biohaven secured a commercial partner for its late-stage epilepsy platform after South Korea’s SK Biopharmaceuticals offered up to $795 million for global rights to Biohaven’s Kv7 ion channel platform, including lead candidate programs. The structure is designed to accelerate the path toward market launch through a partner with execution capacity across regulatory and commercialization needs. The transaction is another signal of how epilepsy remains an active partnering area for late-stage assets tied to ion channel biology—where differentiation may rely on dosing convenience, safety, and long-term disease control. Biohaven’s deal highlights investors’ continued focus on platform-level licensing rather than isolated single-asset transactions, particularly when a pipeline can translate across multiple indications or life-cycle opportunities.